Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Revenue (2019 - 2026)

C4 Therapeutics has reported Revenue over the past 8 years, most recently at $6.2 million for Q1 2026.

  • For Q1 2026, Revenue fell 15.0% year-over-year to $6.2 million; the TTM value through Mar 2026 reached $34.9 million, down 12.37%, while the annual FY2025 figure was $35.9 million, 1.02% up from the prior year.
  • Revenue for Q1 2026 was $6.2 million at C4 Therapeutics, down from $11.0 million in the prior quarter.
  • Over five years, Revenue peaked at $15.4 million in Q3 2024 and troughed at $2.7 million in Q2 2023.
  • A 5-year average of $7.6 million and a median of $6.8 million in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: tumbled 85.79% in 2022 and later skyrocketed 350.68% in 2024.
  • Year by year, Revenue stood at $2.9 million in 2022, then increased by 14.26% to $3.3 million in 2023, then surged by 58.75% to $5.2 million in 2024, then surged by 112.79% to $11.0 million in 2025, then plummeted by 44.15% to $6.2 million in 2026.
  • Business Quant data shows Revenue for CCCC at $6.2 million in Q1 2026, $11.0 million in Q4 2025, and $11.2 million in Q3 2025.